Edgewise Therapeutics, Inc.EWTXNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+31.4%
5Y CAGR+78.5%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+31.4%/yr
Annual compound
5Y CAGR
+78.5%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
18.1x
Strong expansion
Streak
6 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$40.02M+25.6%
2024$31.87M+35.9%
2023$23.45M+33.1%
2022$17.63M+59.9%
2021$11.03M+399.1%
2020$2.21M+69.9%
2019$1.30M-